datetime,headline,summary,related,lang,source
2020-12-02 14:40:00-05:00,San Francisco Bay Area Leaders Extend Support for Women's Higher Education in Asia and the Middle East,"SAN FRANCISCO, Dec. 2, 2020 /PRNewswire/ -- Corporate leaders from Salesforce, Google, PayPal, VISA, BlackRock, Cisco, Adobe, Horizon Therapeutics, KPMG and others, all serving in their personal capacity, have volunteered to come together to support the work of the Asian University for…","CRM,HZNP,HPR",en,PR Newswire
2020-11-27 08:27:03-05:00,"Global Pancreatic Enzyme Replacement Therapy Market To Reflect Impressive Growth Rate by 2027 ||Shire Plc; Sanofi S.A., Biomarin Pharmaceutical Inc., AbbVie Inc, Alexion Pharmaceuticals Inc., Allergan plc, Horizon Pharma Public Limited Company","Data Bridge Market Research has provides the Qualitative and informative knowledge by adding titled “Global Pancreatic Enzyme Replacement Therapy Market, By Type (Enteric Coated and Non-Enteric Coated), Treatment (Medication, Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics,",HPR,en,OpenPR
2020-11-23 08:05:00-05:00,Halozyme Raises Full Year 2020 Guidance,"SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and license agreement with Horizon Therapeutics plc. The Company is raising full year 2020…",HPR,en,PR Newswire
2020-11-23 08:00:00-05:00,"Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology","/PRNewswire/ -- Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license…",HPR,en,PR Newswire
2020-11-22 02:30:00-05:00,"AstraZeneca – Nov 22, 2020 – Eversept Companions, LLC Buys Amarin Corp PLC, Teva Pharmaceutical Industries, Catalent","AstraZeneca - Nov 22, 2020 - Eversept Companions, LLC Buys Amarin Corp PLC, Teva Pharmaceutical Industries, Catalent Inc, Sells TG Therapeutics Inc, AstraZeneca PLC, Horizon Therapeutics PLC -",HPR,en,Fintech Zoom
2020-11-19 15:17:20-05:00,Why HighPoint Resources Stock Is Trading Higher Today,HighPoint Resources (NYSE: HPR ) shares are trading higher on Thursday after the company disclosed that Bonanza Creek Energy had a 46.5% active stake in the company. HighPoint Resources Corp is an … Full story available on Benzinga.com,HPR,en,Benzinga
2020-11-17 09:15:00-05:00,National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) has been named to the National Association for Business Resources’ 2020 list of Best and Brightest Companies to Work For in the Nation. Horizon is one of 151 winning organizations from across the United States out of 1,100 nominations. This year’s award focuses on companies that have been able to pivot their workforces through COVID-19, along with being a leader on racial equity issues. “We’re proud to be named one of the Best and",HPR,en,Business Wire
2020-11-17 07:11:04-05:00,"HighPoint Resources (NYSE:HPR) Issues Earnings Results, Beats Estimates By $0.70 EPS","HighPoint Resources (NYSE:HPR) issued its earnings results on Saturday. The company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.70, reports. HighPoint Resources had a negative net margin of 306.03% and a negative return on equity of 2.76%. NYSE:HPR opened at $6.98 on Tuesday. HighPoint Resources has […]",HPR,en,Transcript Daily
2020-11-16 08:00:00-05:00,First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics Launches First Thyroid Eye Disease (TED) Awareness Week, Nov. 16-20",HPR,en,Business Wire
2020-11-13 08:30:00-05:00,"New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration",DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced new TEPEZZA® (teprotumumab-trbw) data presented at the American Academy of Ophthalmology Annual Meeting.,HPR,en,Business Wire
2020-11-13 08:00:00-05:00,Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Tim Walbert, chairman, president and chief executive officer, has been honored with the 2020 RARE Champion of Hope Industry Partner award by Global Genes, a nonprofit organization that connects, empowers and inspires the rare disease community. Tim received the award at the virtual Global Genes Champions of Hope gala for his leadership in and dedication to the rare disease community, as well as his work advanc",HPR,en,Business Wire
2020-11-12 08:00:00-05:00,Horizon Therapeutics plc to Participate in Upcoming Investor Conferences,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in November: Jefferies Virtual London Healthcare Conference Date: Tuesday, Nov. 17, 2020 Presentation Time: 5:35 p.m. GMT Stifel 2020 Virtual Healthcare Conference Date: Tuesday, Nov. 17, 2020 Presentation Time: 10:40 a.m. ET The conference presentations will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeut",HPR,en,Business Wire
2020-11-09 20:29:04-05:00,Bonanza Creek to buy HighPoint Resources for $375M,DENVER — Denver-based Bonanza Creek Energy Inc. (NYSE: BCEI) is acquiring fellow Denver oil and gas company HighPoint Resources Corp. (NYSE: HPR) in a deal valued at $376 million. Both companies h…,HPR,en,GreeleyTribune
2020-11-09 17:55:24-05:00,"Denver oil, gas producers Bonanza Creek and HighPoint Resources announce $376M merger","Bonanza Creek Energy and HighPoint Resources Corp. announced a merger Monday that is worth $376 million and will create a company with about 206,000 acres of leases in the Denver-Julesburg Basin and a daily production equivalent to 50,000 barrels of oil.",HPR,en,The Denver Post
2020-11-09 12:57:08-05:00,Mid-day market update: Crude Oil jumps over 9%; Highpoint Resources shares plummet,"Midway through trading Monday, the Dow traded up 4.67% to 29,646.85 while the NASDAQ rose 0.82% to 11,992.61. The S&P also rose, gaining 3.14% to…",HPR,en,FXStreet
2020-11-09 11:32:16-05:00,Why HighPoint Resources Stock Is Trading Lower Today,"HighPoint Resources (NYSE: HPR ) shares are trading lower on Monday after the company announced it would merge with Bonanza Creek Energy in an all-stock transaction. HighPoint Resources is an oil and gas exploration and production company. Its operations include the acquisition, exploration, development, and … Full story available on Benzinga.com",HPR,en,Benzinga
2020-11-09 07:48:00-05:00,HighPoint Resources Reports Third Quarter 2020 Financial and Operating Results - Stocks News Feed,"Reported production sales volume of 2.8 million barrels of oil equivalent (“MMBoe”) for the third quarter of 2020, exceeding the high end of guidance by 9% Oil production sales volume of 1.5 million barrels of oil (“MMBbls”) for the third quarter of 2020; 53% of total equivalent production sales volume Cash flow positive… Read More »HighPoint Resources Reports Third Quarter 2020 Financial and Operating Results",HPR,en,Stocks News Feed
2020-11-05 12:23:00-05:00,"TGaS® Advisors, a Division of Trinity Life Sciences, Announces the Third Annual Best of Benchmark Award Winners","WALTHAM, Mass.--(BUSINESS WIRE)-- #bestofbenchmarkawards--Trinity Life Sciences, a leader in global life sciences solutions, announced the winners of the TGaS Best of Benchmark (BoB) Awards. The Awards, which are given for commercial operations excellence within the pharmaceutical industry, were presented to teams at Merck (known as MSD outside the United States and Canada), Gilead, Sanofi, Janssen Oncology, Genentech and Horizon Therapeutics. The BoBs are based on TGaS benchmarking of large, midsize and emerging life",HPR,en,Business Wire
2020-11-04 17:05:00-05:00,HighPoint Resources Announces Rescheduled Third Quarter 2020 Earnings Release Date and Conference Call,"DENVER, Nov. 04, 2020 (GLOBE NEWSWIRE) -- HighPoint Resources Corporation (“HighPoint” or the “Company”) (NYSE: HPR) today announced that the Company has…",HPR,en,GlobeNewswire
2020-11-02 16:08:10-05:00,IN BRIEF: Supreme Court won't hear Horizon appeal over arthritis gel patents,"The U.S. Supreme Court has declined to hear an appeal by Horizon Pharma of an Federal Circuit Court of Appeals decision that invalidated five of its patents on Pennsaid 2%, an NSAID gel for osteoarthritis of the knee.",HPR,en,Reuters
2020-11-02 14:00:00-05:00,Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil,DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator showed improved response rates as compared to KRYSTEXXA monotherapy. Reducing Immunogenicity of Pegloticase (RECIPE) demonstrated that 86.4 percent of patients (19 of 22) receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric aci,HPR,en,Business Wire
2020-11-02 09:17:05-05:00,Horizon Therapeutics Public Limited Company 2020 Q3 - Results - Earnings Call Presentation (NASDAQ:HZNP),The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2020 Q3 earnings call.,HPR,en,Seeking Alpha
2020-11-02 07:55:36-05:00,"Earnings Scheduled For November 2, 2020",Companies Reporting Before The Bell • Itron (NASDAQ: ITRI ) is likely to report quarterly earnings at $0.25 per share on revenue of $540.01 million. • AMC Networks (NASDAQ: AMCX ) is projected to report quarterly earnings at $1.28 per share on revenue of $606.04 million. • BWX Technologies (NYSE: BWXT ) is likely to report quarterly earnings at $0.68 per share on revenue of $499.24 million. • Clorox (NYSE: CLX ) is projected to report quarterly earnings at $2.32 per share on revenue of $1.75 billion. • Camping World Holdings (NYSE: CWH ) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.51 billion. • Eagle Pharmaceuticals (NASDAQ: EGRX ) is likely to report quarterly earnings at $0.28 per share on revenue of $47.02 million. • Exterran (NYSE: EXTN ) is likely to report quarterly loss at $0.48 per share on revenue of $194.32 million. • FirstEnergy (NYSE: FE ) is likely to report quarterly earnings at $0.76 per share on revenue of $2.94 billion. • MGM Growth Properties (NYSE: MGP ) is expected to report quarterly earnings at $0.,"HSIC,HPR",en,Benzinga
2020-11-02 06:58:00-05:00,"Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer","Horizon Therapeutics plc (NASDAQ: HZNP ) today announced that Karin Rosén, M.D., Ph.D., has joined the company as executive vice president, research and development and chief scientific officer, reporting directly to Tim Walbert, chairman, president and chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005247/en/ Karin Rosén, M.D., Ph.D. (Photo: Business Wire) ""We are thrilled to welcome Karin to Horizon during this transformative time in our company's growth,"" said Walbert. ""We have made significant progress during the last three years in building a strong R&D organization and a diversified pipeline. We are confident that Karin's ability to build and lead cross-functional teams, clinical development experience and therapeutic area expertise, will contribute to solidifying our position as a leading rare disease biopharmaceutical company."" Dr. Rosén is an accomplished life sciences … Full story available on Benzinga.",HPR,en,Benzinga
2020-11-01 09:40:39-05:00,"The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings","Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and macroeconomic concerns. Several big-name pharma companies, including Merck & Co. Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ), reported earnings during the week. The earnings news flow was broadly mixed. Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) was among the biggest decliners, as it halted a late-stage trial of its Duchenne muscular dystrophy drug. On the other hand, Scholar Rock Holding Corp. (NASDAQ: SRRK ) was up about over 175% during the week, reacting to positive mid-stage results for spinal muscular atrophy drug. On the COVID-19 front, Regeneron Pharmaceuticals Inc. said it is (NASDAQ: REGN ) halting the Phase 3 trial of its antibody cocktail in patients with severe COVID-19, citing safety issue. Kala Pharmaceuticals Inc. (NASDAQ: KALA ) announced FDA approval for its dry eye disease drug, while Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ) communicated a delay in the decision for its treatment option for chemotherapy-induced neutropenia, as the FDA could not inspect a plant in South Korea due to COVID-19.",HPR,en,Benzinga
2020-10-30 13:22:00-05:00,AGC Biologics und Horizon Therapeutics plc erweitern Partnerschaft,"TEPEZZA® (teprotumumab-trbw), ein Arzneimittel von Horizon, wird von AGC Biologics in neuer Anlage in Boulder, Col. hergestellt SEATTLE, 30 October 2020 /PRNewswire/ -- AGC Biologics, eine weltweit führende Organisation für biopharmazeutische Auftragsentwicklung und -herstellung (CDMO),…",HPR,de,PR Newswire
2020-10-30 08:15:00-05:00,Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune’s Top Workplaces 2020, ranking number two out of other midsize companies in the Chicago area. “Receiving the Top Workplaces award is especially meaningful for us because the Chicago area is home to our U.S. headquarters,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “With a significant portion of our employees living and working in the",HPR,en,Business Wire
2020-10-30 07:00:00-05:00,New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting,DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced new TEPEZZA® (teprotumumab-trbw) data being presented at the American Academy of Ophthalmology Annual Meeting.,HPR,en,Business Wire
2020-10-30 07:00:00-05:00,HighPoint Resources Announces Completion of Reverse Stock Split,"DENVER, Oct. 30, 2020 (GLOBE NEWSWIRE) -- HighPoint Resources Corporation (the ""Company"") (NYSE: HPR) today announced the completion of the Company’s…",HPR,en,GlobeNewswire
2020-10-27 15:06:10-05:00,HighPoint Resources Announces Third Quarter 2020 Earnings Release Date and Conference Call - Stocks News Feed,"Share this Stock Information DENVER, Oct. 27, 2020 (GLOBE NEWSWIRE) — HighPoint Resources Corporation (“HighPoint” or the “Company”) (NYSE:HPR) today announced that the Company plans to issue its third quarter 2020 financial and operating results press release before the market open on Friday, November 6, 2020. Additionally, the Company will host a conference call on… Read More »HighPoint Resources Announces Third Quarter 2020 Earnings Release Date and Conference Call",HPR,en,Stocks News Feed
2020-10-26 07:00:00-05:00,Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is has been named one of the Most Innovative Companies in Chicago by Crain’s Chicago Business. Crain’s compiles the list based on a review by independent intellectual property valuation firm, Ocean Tomo, which evaluates the patents produced each year by Chicago-area companies. Horizon made this year’s list based on its work with its medicine used to treat urea cycle disorders (UCD), a rare genetic disorder",HPR,en,Business Wire
2020-10-24 17:22:46-05:00,Piper Sandler Equities Analysts Boost Earnings Estimates for Horizon Therapeutics Public Limited (NASDAQ:HZNP),"Horizon Therapeutics Public Limited (NASDAQ:HZNP) – Equities research analysts at Piper Sandler raised their Q3 2020 earnings estimates for shares of Horizon Therapeutics Public in a report issued on Wednesday, October 21st. Piper Sandler analyst D. Amsellem now anticipates that the biopharmaceutical company will post earnings per share of $0.89 for the quarter, up from […]",HPR,en,Daily Political
2020-10-24 01:38:47-05:00,HighPoint Resources (NYSE:HPR) Upgraded to “Hold” by Zacks Investment Research,"Zacks Investment Research upgraded shares of HighPoint Resources (NYSE:HPR) from a sell rating to a hold rating in a report released on Wednesday morning, Zacks.com reports. According to Zacks, “HighPoint Resources Corporation is an exploration and production company. It focuses on the development of oil and natural gas assets primarily in the Denver-Julesburg Basin of […]",HPR,en,Stock Observer
2020-10-23 20:30:57-05:00,Horizon Therapeutics Public Limited (NASDAQ:HZNP) Forecasted to Post Q3 2020 Earnings of $0.89 Per Share,"Horizon Therapeutics Public Limited (NASDAQ:HZNP) – Stock analysts at Piper Sandler raised their Q3 2020 earnings estimates for shares of Horizon Therapeutics Public in a note issued to investors on Wednesday, October 21st. Piper Sandler analyst D. Amsellem now anticipates that the biopharmaceutical company will post earnings per share of $0.89 for the quarter, up […]",HPR,en,The Lincolnian
2020-10-23 07:00:00-05:00,Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named one of the top 100 adoption-friendly workplaces in the United States by the Dave Thomas Foundation for Adoption, ranking number 39 overall and number two in the pharmaceutical category. The list recognizes organizations with the most robust adoption benefit programs, comparing financial reimbursement and paid leave offered to employees who adopt, based on a survey of organizations across the",HPR,en,Business Wire
2020-10-23 03:10:42-05:00,HighPoint Resources (NYSE:HPR) Stock Rating Upgraded by Zacks Investment Research,"HighPoint Resources (NYSE:HPR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “HighPoint Resources Corporation is an exploration and production company. It focuses on the development of oil and natural gas assets primarily in the Denver-Julesburg Basin of Colorado. […]",HPR,en,Transcript Daily
2020-10-22 13:42:44-05:00,HighPoint Resources (NYSE:HPR) Shares Up 21.5%,"HighPoint Resources Co. (NYSE:HPR) shot up 21.5% during trading on Thursday . The stock traded as high as $0.17 and last traded at $0.16. 13,842,427 shares traded hands during trading, an increase of 254% from the average session volume of 3,911,332 shares. The stock had previously closed at $0.13. Several research firms have commented on […]",HPR,en,The Olympia Report
2020-10-22 09:00:00-05:00,New Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout,DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new research from the PROspective sTudy of pEglotiCase in Transplant patients (PROTECT) trial supporting the use of KRYSTEXXA (pegloticase injection) for people who are living with chronic gout refractory to conventional therapies (also known as uncontrolled gout) and have undergone a kidney transplant. These data are being presented as part of this year’s American Society of Nephrology (ASN) Ki,HPR,en,Business Wire
2020-10-22 06:17:04-05:00,"HighPoint Resources Corporation (OTCMKTS:XOGAQ) to Post Q3 2020 Earnings of ($0.07) Per Share, KeyCorp Forecasts","HighPoint Resources Corporation (OTCMKTS:XOGAQ) – Stock analysts at KeyCorp raised their Q3 2020 EPS estimates for shares of HighPoint Resources in a research note issued to investors on Monday, October 19th. KeyCorp analyst L. Mariani now anticipates that the company will earn ($0.07) per share for the quarter, up from their prior estimate of ($0.14). […]",HPR,en, Dakota Financial News
2020-10-22 00:58:41-05:00,"HighPoint Resources Stock Set to Reverse Split on Friday, October 30th (NYSE:HPR)","Shares of HighPoint Resources Co. (NYSE:HPR) are scheduled to reverse split on the morning of Friday, October 30th. The 1-50 reverse split was announced on Tuesday, October 20th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, October 29th. HPR opened at $0.13 on Thursday. The business’s 50-day […]",HPR,en, Dakota Financial News
2020-10-21 20:14:41-05:00,"HighPoint Resources (NYSE:HPR) Shares Scheduled to Reverse Split on Friday, October 30th","HighPoint Resources Co. (NYSE:HPR) shares are going to reverse split on Friday, October 30th. The 1-50 reverse split was announced on Tuesday, October 20th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, October 29th. NYSE HPR opened at $0.13 on Thursday. The stock has a market capitalization […]",HPR,en,The Lincolnian
2020-10-21 17:14:41-05:00,"HighPoint Resources Stock to Reverse Split on Friday, October 30th (NYSE:HPR)","Shares of HighPoint Resources Co. (NYSE:HPR) are going to reverse split on Friday, October 30th. The 1-50 reverse split was announced on Tuesday, October 20th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, October 29th. Shares of NYSE:HPR opened at $0.13 on Thursday. The business’s fifty day […]",HPR,en,Daily Political
2020-10-21 13:02:44-05:00,Horizon Therapeutics Public Limited (NASDAQ:HZNP) Receives Average Rating of “Buy” from Brokerages,"Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP) have been given an average recommendation of “Buy” by the sixteen brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has assigned a […]",HPR,en,The Olympia Report
2020-10-21 06:32:45-05:00,HighPoint Resources (NYSE:HPR) Shares Down 9%,"HighPoint Resources Co. (NYSE:HPR) dropped 9% during trading on Monday . The company traded as low as $0.19 and last traded at $0.19. Approximately 5,506,734 shares traded hands during mid-day trading, an increase of 45% from the average daily volume of 3,810,887 shares. The stock had previously closed at $0.21. HPR has been the subject […]",HPR,en,Zolmax News
2020-10-20 13:58:47-05:00,Horizon Therapeutics Public (NASDAQ:HZNP) Shares Down 5.3%,"Horizon Therapeutics Public Limited (NASDAQ:HZNP)’s stock price fell 5.3% during mid-day trading on Tuesday . The company traded as low as $73.33 and last traded at $74.31. 4,242,134 shares traded hands during trading, an increase of 91% from the average session volume of 2,216,988 shares. The stock had previously closed at $78.46. A number of […]",HPR,en,US Banking News
2020-10-20 11:06:44-05:00,HighPoint Resources (NYSE:HPR) Shares Gap Down to $0.19,"HighPoint Resources Co. (NYSE:HPR)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $0.19, but opened at $0.18. HighPoint Resources shares last traded at $0.17, with a volume of 151,547 shares changing hands. Several analysts have weighed in on the company. ValuEngine lowered HighPoint Resources from a “sell” […]",HPR,en,Transcript Daily
2020-10-20 07:18:00-05:00,HighPoint Resources Announces 1-for-50 Reverse Stock Split,"DENVER, Oct. 20, 2020 (GLOBE NEWSWIRE) -- HighPoint Resources Corporation (the ""Company"") (NYSE: HPR) today announced that the Company will effect a…",HPR,en,GlobeNewswire
2020-10-20 07:00:00-05:00,Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award,DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics today announced that TEPEZZA® (teprotumumab-trbw) has been selected as a winner of the 19th Annual Chicago Innovation Award,HPR,en,Business Wire
2020-10-19 05:58:54-05:00,Brokerages Set Horizon Therapeutics Public Limited (NASDAQ:HZNP) Target Price at $77.93,"Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP) have been given a consensus rating of “Buy” by the sixteen research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has […]",HPR,en,Stock Observer
2020-10-16 07:30:00-05:00,FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been selected to FORTUNE’s Best Medium Workplaces 2020 list for the fifth consecutive year. Horizon ranked 10th out of 100 other medium-sized companies. “This recognition from FORTUNE and Great Place to Work is the result of our deep, ongoing efforts to elevate the Horizon experience for all our team members,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “We have worked ha",HPR,en,Business Wire
2020-10-08 07:15:00-05:00,New Data Evaluating KRYSTEXXA® (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that data from the investigator-initiated trial, REduCing Immunogenicity to PegloticasE (RECIPE), will be presented during ACR Convergence Nov. 5-9, 2020. Additional studies on the concomitant use of KRYSTEXXA (pegloticase injection) with an immunomodulator to optimize the treatment for people living with chronic gout refractory to conventional therapies (also known as uncontrolled gout) will also be presented. “In",HPR,en,Business Wire
2020-10-08 07:00:00-05:00,"Horizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020","DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2020 financial results will be released on Monday, Nov. 2, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ens",HPR,en,Business Wire
2020-10-07 07:00:00-05:00,Horizon Therapeutics plc Named One of San Francisco Bay Area’s Best and Brightest Companies to Work For,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of “San Francisco Bay Area's Best and Brightest Companies to Work For.” This is the first year that Horizon has been named to the list since opening the company’s South San Francisco office in November 2019. “It’s an honor to be recognized as one of the Best and Brightest Companies to Work For given our growing presence and strong commitment to the Bay Area,” said Srini Ramanathan, Ph.D.,",HPR,en,Business Wire
2020-10-06 08:14:41-05:00,"Releases New Report on the Antigout Drug Market 2020-2025 | Top Key Players - Novartis, Takeda, Aspen, Teijin Pharma, Horizon Pharma","The Global Antigout Drug Market is comprehensively and Insightful information in the report, taking into consideration various factors such as competition, regional growth, segmentation, and Antigout Drug Market size by value and volume. This is an excellent research study specially",HPR,en,OpenPR
2020-10-06 07:24:11-05:00,"The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) argenx SE – ADR (NASDAQ: ARGX ) (presented positive new data from a Phase 3 trial evaluating efgartigimod in patients with generalized myasthenia gravis) Ascendis Pharma A/S (NASDAQ: ASND ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) (went public Friday) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) Cytokinetics, Inc. (NASDAQ: CYTK ) (reacted to presentations at the Heart Failure Society of America virtual meeting) Eidos Therapeutics Inc (NASDAQ: EIDX ) - announced a deal to be bought by BridgeBio Pharma Inc (NASDAQ: BBIO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) Myokardia Inc (NASDAQ: MYOK ) - announced a deal to be bought by Bristol-Myers Squibb Co (NYSE: BMY ) for $13.",HPR,en,Benzinga
2020-10-01 15:00:00-05:00,Horizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of Adoption,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) was named as a 2020 Angels in Adoption® Honoree for the company’s outstanding advocacy for adoption of children living with rare diseases. The Congressional Coalition on Adoption Institute (CCAI), which coordinates the Angels in Adoption® Program, honored Horizon at its virtual gala on Sept. 30, 2020. The company was nominated by U.S. Senator Tammy Duckworth (D-IL). Horizon was recognized for its innovative #RAREis Adoption Fund p",HPR,en,Business Wire
2020-09-16 07:00:28-05:00,"The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO","Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than doubled on its Wall Street debut) Repare Therapeutics Inc (NASDAQ: RPTX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) Histogen Inc (NASDAQ: HSTO ) PainReform Ltd (NASDAQ: PRFX ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Roche Gets Label Expansion For Cancer Screening Test Roche Holdings AG Basel (OTC: RHHBY ) announced FDA approval for the expanded use of CINtec PLUS Cytology, its first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus.",HPR,en,Benzinga
2020-09-16 07:00:00-05:00,MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the complete dataset on the primary endpoint from its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (MIRROR) open-label trial in the Journal of Rheumatology [https://doi.org/10.3899/jrheum.200460]. Horizon’s MIRROR clinical program includes the completed multi-center, open-label trial as well as an ongoing randomized controlled trial (RCT). The tri",HPR,en,Business Wire
2020-09-02 08:00:00-05:00,Horizon Therapeutics plc Named to the 2020 PEOPLE “50 Companies That Care” List,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of PEOPLE’s “50 Companies That Care” for 2020. The 2020 “50 Companies That Care” list spotlights 50 U.S. companies with 1,000 or more employees and their response to taking care of their employees, their communities and the world during the COVID-19 crisis. The list will be featured in the Sept. 14, 2020 print issue of PEOPLE. “It is a special honor to be recognized by PEOPLE and Great Pl",HPR,en,Business Wire
2020-08-11 16:00:00-05:00,Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 13,570,000 of its ordinary shares at a price to the public of $71.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,770,000 additional ordinary shares. The net proceeds to the Company from this offering are expected to be approximately $919.3 million, after deducting underwriting discounts and other estimated o",HPR,en,Business Wire
2020-08-10 13:57:12-05:00,Bullish Signal Could Catapult Pharma Stock Higher,Horizon Therapeutics stock is flashing a bull signal that could catapult it to a new record high,HPR,en,Schaeffers Investment Research
2020-08-10 08:00:00-05:00,Horizon Therapeutics Named one of the Best Places to Work in Chicago by Crain’s Chicago Business,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the Crain’s Chicago Business 2020 Best Places to Work in Chicago list. “It’s a tremendous honor that Crain’s Chicago Business ranked us among the Best Places to Work in Chicago where many Horizon employees live and work,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Despite these challenging times, working at Horizon remains grounded in the strength of our c",HPR,en,Business Wire
2020-08-06 22:20:00-05:00,Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the pricing of its underwritten public offering of 11,800,000 of its ordinary shares at a price to the public of $71.00 per share. The net proceeds to the Company from this offering are expected to be approximately $798.9 million, after deducting underwriting discounts and other estimated offering expenses payable by the Company. The Company has also granted the underwriters a 30-day option to purchase up to an add",HPR,en,Business Wire
2020-08-06 08:00:00-05:00,Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the 2020 Fortune Best Workplaces for Millennials™ list. Horizon ranked 7th among 25 companies in the small and medium company category in its first year on the list. “We’re proud that Fortune and Great Place to Work recognized the focus we put on developing employees at each phase of their careers, including those in the beginning stages,” said Tim Walbert, chairman, president and chief ex",HPR,en,Business Wire
2020-08-05 15:01:00-05:00,Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is offering to sell $700,000,000 of its ordinary shares in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $105,000,000 of ordinary shares in the public offering. Citigroup, Morgan Stanley, J.P. Morgan, Piper Sandler and Stifel are acting as joint book-running managers for the offering. Cowen is acting as a financial advisor",HPR,en,Business Wire
2020-08-05 08:38:00-05:00,"Thinking about buying stock in Sorrento Therapeutics, Aerpio Pharmaceuticals, Horizon Therapeutics, Riot Blockchain, or Royal Caribbean Cruises?","NEW YORK, Aug. 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, ARPO, HZNP, RIOT, and RCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….",HPR,en,PR Newswire
2020-08-05 02:46:00-05:00,Recap: Horizon Therapeutics Q2 Earnings,Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 18.37% over the …,HPR,en,Benzinga
2020-07-24 15:02:00-05:00,HighPoint Resources Announces Second Quarter 2020 Earnings Release Date and Conference Call,"DENVER, July 24, 2020 (GLOBE NEWSWIRE) -- HighPoint Resources Corporation (“HighPoint” or the “Company”) (NYSE: HPR) today announced that the Company…",HPR,en,GlobeNewswire
2020-07-23 07:25:53-05:00,"The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results","Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.",HPR,en,Benzinga
2020-07-22 07:00:00-05:00,Target Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for People Living with Uncontrolled Gout,DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company has reached target patient enrollment for its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA [(MIRROR) randomized controlled trial (RCT)]. MIRROR RCT is the largest randomized trial to evaluate the efficacy and safety of the concomitant use of KRYSTEXXA® (pegloticase injection) with methotrexate as an immunomodulator to help more people with chronic g,HPR,en,Business Wire
2020-07-22 06:24:35-05:00,"The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat","Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer COVID-19 diagnostics testing to the NFL) ResMed Inc. (NYSE: RMD ) Retrophin Inc (NASDAQ: RTRX ) Trevena Inc (NASDAQ: TRVN ) Twist Bioscience Corp (NASDAQ: TWST ) Veracyte Inc (NASDAQ: VCYT ) West Pharmaceutical Services Inc.","HPR,HTBX",en,Benzinga
2020-06-05 10:31:51-05:00,Why Is Horizon Therapeutics (HZNP) Up 13.2% Since Last Earnings Report?,Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,HPR,en,Zacks Investment Research
2020-04-29 11:34:02-05:00,Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?,Horizon Therapeutics (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,HPR,en,Zacks Investment Research
2020-04-27 07:10:00-05:00,Horizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets are now available in the United States and can be ordered in 75 mg and 300 mg dosage strengths for adults and children one year of age and older living with nephropathic cystinosis. The U.S. Food and Drug Administration (FDA) approved this new dosage form in February 2020. In the United States, PROCYSBI is now available in two forms: te",HPR,en,Business Wire
2020-04-15 11:10:10-05:00,Can Horizon Therapeutics (HZNP) Keep the Earnings Surprise Streak Alive?,Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,HPR,en,Zacks Investment Research
2020-04-15 07:00:00-05:00,"Horizon Therapeutics plc to Release First-Quarter 2020 Financial Results and Host Webcast on May 6, 2020","DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2020 financial results will be released on Wednesday, May 6, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to e",HPR,en,Business Wire
2020-04-09 08:00:00-05:00,Horizon Therapeutics plc Named One of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ:HZNP) today announced it has been selected as one of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®. ""Providing meaningful support for our employees is always paramount, which is why we take special pride in this prestigious honor that recognizes the top companies in the health care and biopharma industries,"" said Tim Walbert, chairman, president and chief executive officer, Horizon. “We recogni",HPR,en,Business Wire
2020-04-02 07:00:00-05:00,"Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline","DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825). Under terms of the agreement, Horizon acquired Curzion for a $45 million upfront cash payment with additional payments contingent on the achievement of development and regulatory milestones. C",HPR,en,Business Wire
2020-03-27 10:31:03-05:00,Horizon Therapeutics (HZNP) Down 16.6% Since Last Earnings Report: Can It Rebound?,Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,HPR,en,Zacks Investment Research
2020-03-03 08:00:00-05:00,Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Down and Out Kidney, a campaign to highlight the damaging effects associated with the accumulation of uric acid and gout in people with chronic kidney disease (CKD). Down and Out Kidney features an immersive animated video that casts the kidney as the unsuspecting lead character whose growing interaction with uric acid endangers not only himself, but his friends – foot, hand, bone and heart. The novel",HPR,en,Business Wire
2020-02-28 08:00:00-05:00,Horizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced a $1 million commitment over five years to establish the #RAREis scholarship, a program that will be made available by the EveryLife Foundation for Rare Diseases. The #RAREis scholarship will support the pursuit of life enrichment activities for adults living with rare diseases for a variety of educational pursuits, including educational courses, travel stipends for rare disease conferences and obtaining two-and fo",HPR,en,Business Wire
2020-02-18 08:30:00-05:00,Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March: Cowen and Company 40th Annual Health Care Conference Date: Tuesday, Mar. 3, 2020 Presentation Time: 12 p.m. ET Location: Boston The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available for the event. About Horizon Horizon is",HPR,en,Business Wire
2020-02-18 08:00:00-05:00,Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis. This new dosage form provides another option for people living with cystinosis, in addition to the currently available PROCYSBI capsules. Both the capsules and the packets contain the same PROCY",HPR,en,Business Wire
2020-02-04 08:00:00-05:00,"Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020","DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the",HPR,en,Business Wire
2020-01-24 16:05:00-05:00,Horizon Therapeutics plc Announces Changes in Research and Development Organization,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and external search; Srini Ramanathan, Ph.D., group vice president, development sciences and San Francisco site head and Melanie Gloria, senior vice president, R&D operations, will report to Timothy Walbert, chairman, president and chief executive offi",HPR,en,Business Wire
2020-01-22 04:03:00-05:00,Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza,"Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.",HPR,en,Zacks Investment Research
2020-01-13 08:15:00-05:00,Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it is increasing the peak U.S. annual net sales expectations for its key growth drivers KRYSTEXXA and teprotumumab, as well as providing several pipeline updates. “As we enter 2020, Horizon is in its strongest position ever,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “We believe KRYSTEXXA and teprotumumab each has the potential for more than $1 billion in peak U.S. annual",HPR,en,Business Wire
2020-01-13 08:05:00-05:00,MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® (pegloticase injection) provided an increased durability of response for people living with chronic gout refractory to conventional therapies – also known as uncontrolled gout. Data from the Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (MIRROR OL) shows that 79 percent, or 11 of 1",HPR,en,Business Wire
2020-01-03 03:58:00-05:00,Horizon Therapeutics' Stock Up in a Year on Pipeline Progress,Horizon Therapeutics' (HZNP) shares have risen in the past year owing to the development of its pipeline candidates.,HPR,en,Zacks Investment Research
2019-12-16 03:46:00-05:00,Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote,"Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.",HPR,en,Zacks Investment Research
2019-12-09 08:00:00-05:00,Horizon Therapeutics plc to Present at the 38th Annual J.P. Morgan Healthcare Conference,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 38th Annual J.P. Morgan Healthcare Conference. Timothy Walbert, chairman, president and chief executive officer will present at 5 p.m. PT on Jan. 15, 2020. The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available for the event. About Horizon Horizon is fo",HPR,en,Business Wire
2019-12-06 11:31:25-05:00,Why Is Horizon Therapeutics (HZNP) Up 7.5% Since Last Earnings Report?,Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,HPR,en,Zacks Investment Research
2019-11-27 07:26:05-05:00,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ardelyx Inc (NASDAQ: ARDX ) ( announced a research collaboration with Japan's Kyowa Kirin and an investment in the company by the latter) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(reacted to its full-year results) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) ChemoCentryx Inc (NASDAQ: CCXI )( announced positive late-stage results for rare inflammation disease drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Global Blood Therapeutics Inc (NASDAQ: GBT )(announced FDA nod for sickle cell disease drug) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co., Inc. (NYSE: MRK )(Keytruda was approved in China as a first-line treatment for lung cancer, in combination with chemotherapy) Molecular Templates Inc (NASDAQ: …",HPR,en,Benzinga
2019-11-26 08:06:41-05:00,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.",HPR,en,Benzinga
2019-11-22 08:00:00-05:00,Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor. The 20,000 square-foot facility will feature laboratory space that will enable formulation and process development for manufacturing, as well as bioanalytical method development and other R&D functions. “This is a significant step as we continue to grow our manufacturing and R&D capability to address patient needs th",HPR,en,Business Wire
2019-11-14 09:30:00-05:00,FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been named to FORTUNE Magazine’s 2019 “Best Workplaces for Parents” list, which highlights companies that best support employees, regardless of parenting status, as well as offer quality benefits including generous parental leave, adoption, flexible scheduling and dependent health care options. Horizon ranked 19 out of 50 companies. “As both a father, I feel strongly about creating and maintaining a wor",HPR,en,Business Wire
2019-11-13 16:15:00-05:00,Horizon Therapeutics plc to Participate in Upcoming Investor Conferences,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming conferences: Stifel 2019 Healthcare Conference Date: Tuesday, Nov. 19, 2019 Presentation Time: 9:45 a.m. EST Location: New York Jefferies 2019 London Healthcare Conference Date: Wednesday, Nov. 20, 2019 Presentation Time: 8:00 a.m. GMT Location: London Piper Jaffray 31st Annual Healthcare Conference Date: Tuesday, Dec. 3, 2019 Presentation Time: 12:00 p.m.",HPR,en,Business Wire
2019-11-12 17:56:06-05:00,Horizon Therapeutics (NASDAQ:HZNP) Price Target Increased to $36.00 by Analysts at Cantor Fitzgerald,"Horizon Therapeutics (NASDAQ:HZNP) had its target price increased by Cantor Fitzgerald from $32.00 to $36.00 in a research report sent to investors on Friday morning, The Fly reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on HZNP. Bank of America assumed coverage on Horizon […]",HPR,en,Modern Readers
2019-11-11 05:57:44-05:00,3 Market-Beating Stocks for Your 2020 Radar,"With stocks reaching all-time highs as we round out the calendar year, all eyes are on the market. But which names are worthy of all this investor attention? Wall Street analysts recommend focusing on the long-term outlook in order to zero in on high-growth tickers. We mean the stocks best positioned to dish out huge returns in the years to come. That being said, the economic uncertainty going into 2020 has made it increasingly difficult to pinpoint the names capable of leading the way. However, this is not to say that investment opportunities with stand-out growth prospects can’t be found. We took advantage of the comprehensive investing tools from TipRanks.com to uncover 3 stocks that have what it takes to beat the market. Not to mention each of the stocks has racked up enough bullish ratings over the last three months to earn a “Strong Buy” consensus rating. Let’s see why analysts view these stocks as buying propositions. Anaplan Inc. ( PLAN ) Anaplan offers a cloud-based planning platform to help organizations make better and more informed decisions.",HPR,en,Nasdaq
2019-11-08 09:30:00-05:00,The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace,"DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) has been awarded a Top Workplaces 2019 honor by the Chicago Tribune. This is the fifth consecutive year Horizon has received this honor. “We take tremendous pride in being named a Top Workplaces company by the Chicago Tribune,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “With the Chicago area serving as home to our U.S. operations, this award reflects our strong dedication to this great communi",HPR,en,Business Wire
2019-11-05 06:53:31-05:00,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Amgen, Inc. (NASDAQ: AMGN ) Beigene Ltd (NASDAQ: BGNE ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(reacted to its third-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) (IPOed Oct. 31) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Recro Pharma Inc (NASDAQ: REPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 4) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Rockwell Medical Inc (NASDAQ: RMTI ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Stocks In Focus Seattle Genetics Claims Rights To Disputed Antibody-Drug Conjugate Intellectual Property Following the filing of a declaratory judgment action by DAIICHI SANKYO/S ADR (OTC: DSNKY ), Seattle Genetics, Inc. (NASDAQ: SGEN ) said the antibody-drug conjugate tech used in Daiichi Sankyo's metastatic cancer drug candidate DS-820 , among others, rightfully belongs to it. ""The linker and other ADC technology used in these drug candidates are improvements to Seattle Genetics' pioneering ADC technology, the ownership of which are automatically assigned to Seattle Genetics under the terms of the agreement,"" the company said.","HPR,HSDT",en,Benzinga
2019-10-30 09:33:59-05:00,Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for,Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,HPR,en,Zacks Investment Research
2019-10-10 19:12:20-05:00,IN BRIEF: Fed Circuit shuts down Actavis generic for Horizon’s osteoarthritis drug,"Actavis Laboratories UT cannot offer a generic version of Horizon Pharma’s Pennsaid 2% serum until one of the patents on it expires, the U.S. Court of Appeals for the Federal Circuit held Thursday.",HPR,en,Reuters
2019-09-12 09:02:00-05:00,Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus,"Shares of Horizon Therapeutics (HZNP) have gained year to date, owing to its focus on label expansions and pipeline development.",HPR,en,Zacks Investment Research
2019-09-12 04:02:00-05:00,Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus,"Shares of Horizon Therapeutics (HZNP) have gained year to date, owing to its focus on label expansions and pipeline development.",HPR,en,Zacks Investment Research
2019-09-10 01:59:00-05:00,Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review,"Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.",HPR,en,Zacks Investment Research
2019-09-06 08:31:09-05:00,Why Is Horizon Therapeutics (HZNP) Down 3.3% Since Last Earnings Report?,Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,HPR,en,Zacks Investment Research
2019-08-14 09:47:30-05:00,"Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade","Horizon Therapeutics PLC (NASDAQ: HZNP ), an actively traded small-cap biotech, is poised for further upside in the near-term on its product strength, according to BMO Capital Markets. The Analyst Gary Nachman upgraded Horizon Therapeutics from Market Perform to Outperform and lifted the price target from $29 to $36. The Thesis Horizon's Krystexxa, indicated to treat gout, catalyzed a strong second quarter for the company and is likely to be a bigger source of upside going forward, Nachman said in a Tuesday upgrade note. (See his track record here .) The drug fetched sales of $13 million by virtue of its more than 20% growth, significantly exceeding expectations, the analyst said. The … Full story available on Benzinga.com",HPR,en,Benzinga
2019-08-07 07:45:05-05:00,Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates,"Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 36.84% and 7.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?",HPR,en,Zacks Investment Research
2019-07-31 09:36:09-05:00,Earnings Preview: Horizon Therapeutics (HZNP) Q2 Earnings Expected to Decline,Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,HPR,en,Zacks Investment Research
2019-07-19 08:41:00-05:00,Horizon's NDA for Procysbi New Dosage Form Accepted by FDA,The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.,HPR,en,Zacks Investment Research
2019-07-11 08:05:00-05:00,Horizon Therapeutics Files BLA to FDA for Eye Disease Drug,Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.,HPR,en,Zacks Investment Research
2019-05-29 08:44:46-05:00,Horizon Pharma teams up with Invitae in UCD testing,No summary available.,HPR,en,Seeking Alpha
2019-05-23 08:25:48-05:00,Tracking John Paulson's Paulson & Company Portfolio - Q1 2019 Update,No summary available.,HPR,en,Seeking Alpha
2019-05-15 16:31:32-05:00,"In win for Mylan, appeals court axes patents on arthritis drug Vimovo",A federal appeals court on Wednesday eased the way for Mylan NV and other generic drug companies to launch a generic version of Horizon Pharma PLC and Nuvo Pharmaceutical Inc's arthritis drug Vimovo.,HPR,en,Reuters
2019-05-15 12:32:39-05:00,Horizon on short end of appeal of Vimovo patents,No summary available.,HPR,en,Seeking Alpha
2019-05-15 09:35:12-05:00,Horizon down 2% on reported negative ruling on Vimovo patent,No summary available.,HPR,en,Seeking Alpha
2019-05-09 17:17:00-05:00,Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates,"Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.",HPR,en,Zacks Investment Research
2019-05-08 12:44:19-05:00,Horizon Therapeutics PLC (HZNP) CEO Tim Walbert on Q1 2019 Results - Earnings Call Transcript,No summary available.,HPR,en,Seeking Alpha
2019-05-08 12:23:41-05:00,Horizon Pharma PLC (HZNP) Q1 2019 Earnings Call Transcript,"HZNP earnings call for the period ending March 31, 2019.",HPR,en,The Motley Fool
2019-05-08 09:36:08-05:00,Horizon Pharma plc 2019 Q1 - Results - Earnings Call Slides,No summary available.,HPR,en,Seeking Alpha
2019-05-08 07:25:08-05:00,Horizon Pharma (HZNP) Q1 Earnings and Revenues Top Estimates,"Horizon Pharma (HZNP) delivered earnings and revenue surprises of 200.00% and 18.40%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?",HPR,en,Zacks Investment Research
2019-05-08 06:43:37-05:00,Horizon Pharma +3% on Q1 beat; ups guidance,No summary available.,HPR,en,Seeking Alpha
2019-05-08 06:07:14-05:00,"Horizon Pharma beats by $0.18, beats on revenue",No summary available.,HPR,en,Seeking Alpha
2019-05-07 16:30:01-05:00,Horizon Pharma Q1 2019 Earnings Preview,"Horizon Pharma (NASDAQ:HZNP) is scheduled to announce Q1 earnings results on Wednesday, May 8th, before market open. The consensus EPS Estimate is $0.12 an",HPR,en,Seeking Alpha
2019-05-01 09:32:45-05:00,Horizon Pharma (HZNP) Reports Next Week: Wall Street Expects Earnings Growth,Horizon Pharma (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,HPR,en,Zacks Investment Research
2019-04-29 09:11:24-05:00,Biotech News Recap: Portola Gains Approval In Europe For Ondexxya,No summary available.,HPR,en,Seeking Alpha
2019-04-28 14:22:24-05:00,Horizon Pharma: Teprotumumab To Become A Key Commercial Asset In The 2020s,No summary available.,HPR,en,Seeking Alpha
2019-04-22 14:27:33-05:00,Acer's Upcoming Catalysts,No summary available.,HPR,en,Seeking Alpha
2019-04-16 13:04:58-05:00,Recordati to seek Canadian approval for kidney disease drug,"Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.",HPR,en,Reuters
2019-04-10 09:10:17-05:00,Why the Earnings Surprise Streak Could Continue for Horizon Pharma (HZNP),Horizon Pharma (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,HPR,en,Zacks Investment Research
2019-03-29 08:57:37-05:00,Selecta Bio launches study comparing SEL-212 to Horizon's Krystexxa; shares up 3%,No summary available.,HPR,en,Seeking Alpha
2019-03-11 09:48:20-05:00,Horizon Pharma: Teprotumumab Opportunity Not Fully Priced In,No summary available.,HPR,en,Seeking Alpha
2019-03-07 06:47:31-05:00,Horizon Pharma prices stock offering at $24.50; shares down 4% premarket,No summary available.,HPR,en,Seeking Alpha
2019-03-05 17:24:29-05:00,Horizon Pharma -2.6% after DOJ demand over payments to PBMs,No summary available.,HPR,en,Seeking Alpha
2019-03-04 16:31:55-05:00,Horizon Pharma commences $300M equity offering,No summary available.,HPR,en,Seeking Alpha
2019-02-28 12:41:31-05:00,"HPQ, JCP, BOX and WES among notable midday movers",No summary available.,HPR,en,Seeking Alpha
2019-02-28 11:03:10-05:00,Horizon Pharma leads healthcare gainers; Novavax leads the losers,No summary available.,HPR,en,Seeking Alpha
2019-02-28 08:50:36-05:00,Horizon Pharma up 23% premarket on positive teprotumumab data,No summary available.,HPR,en,Seeking Alpha
2019-02-27 13:12:05-05:00,Horizon Pharma plc (HZNP) CEO Timothy Walbert on Q4 2018 Results - Earnings Call Transcript,No summary available.,HPR,en,Seeking Alpha
2019-02-27 08:10:06-05:00,Horizon Pharma up 7% on Q4 beat,No summary available.,HPR,en,Seeking Alpha
2019-02-27 08:04:27-05:00,Horizon Pharma plc 2018 Q4 - Results - Earnings Call Slides,No summary available.,HPR,en,Seeking Alpha
2019-02-27 07:01:44-05:00,"Horizon Pharma beats by $0.13, beats on revenue",No summary available.,HPR,en,Seeking Alpha
2019-02-26 17:30:27-05:00,Horizon Pharma Q4 2018 Earnings Preview,No summary available.,HPR,en,Seeking Alpha
